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Introduction
Current approaches to achieve a cure for HIV infection include 
the administration of latency-reversing agents (LRAs) to induce 
latently HIV-infected cells to reexpress virions or viral antigens, 
in concert with immunotherapies to clear these newly vulnerable 
targets. Sustained or repeated disruption of latency by LRAs is par-
amount for the success of this approach. Therefore, defining effec-
tive LRA dosing regimens that lead to repeated HIV RNA expres-
sion and HIV antigen presentation is an important first step toward 
targeting persistent HIV infection. To date, histone deacetylase 
(HDAC) inhibitors are the most well-characterized class of LRAs 
studied in humans as a modality to disrupt HIV latency in vivo. 
HDACs are a class of enzymes that repress transcription primar-
ily through their ability to covalently modify the lysine tail of core 
histones of nucleosomes through deacetylation, but can also exert 
influences on cellular activities that are independent of transcrip-
tional repression (reviewed in ref. 1). Deacetylation of lysine resi-
dues on histone tails decreases the access of transcription factors 
to the DNA and recruits histone-modifying and chromatin com-
plexes that result in transcriptional repression. HDAC inhibitors 
generally function by blocking the catalytic domain of HDACs and 
thereby interfering with their deacetylase activity. Of the 4 known 
classes of HDACs (class I, class IIa, class IIb, class III, and class 
IV), the class I HDACs are reported to be important in HIV tran-
scriptional repression (2). Most HDAC inhibitors investigated in 
the clinic as anti-HIV latency therapeutics are selective for class I 
HDACs or have broad activity against HDACs (1, 3).
We first reported that a single 400-mg dose of vorinostat 
(VOR) given to HIV-infected but stably aviremic individuals on 
antiretroviral therapy (ART) can increase HIV RNA in resting 
CD4+ T cells, demonstrating the reversibility of latency in humans 
(4), a finding corroborated in studies of total CD4+ T cells using 
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circulating resting CD4+ T cells obtained via apheresis. Changes 
in HIV RNA levels within the resting CD4+ T cell pool are most 
likely to represent the true reversal of latency and recent upreg-
ulation of HIV proviral expression, rather than HIV expression in 
the “active reservoir” of HIV-RNA–expressing cells found in cir-
culating total CD4+ T cell pools (15). Further, the measurement 
of resting CD4+ T cell–associated HIV RNA (rca-HIV RNA) in 36 
replicate pools of 1 million resting CD4+ T cells ensures a robust 
and precise assessment of changes in HIV RNA expression (4). 
Thus, we used this approach to explore the optimal VOR dosing 
interval that would result in consistent and sustained reversal of 
HIV latency. Further, as an antiviral immune response is thought 
to be required to clear persistent HIV infection following LRA 
activity, we measured immune function following prolonged 
exposure to VOR in vivo.
Results
In vitro modeling of effective VOR dosing. Prior to executing a clinical 
study (Figure 1), we used an in vitro approach to explore the dosing 
schedule that might lead to consistent and sustained expression of 
rca-HIV RNA after exposure of resting CD4+ T cells to VOR. To do 
this, we took advantage of previously reported in vivo VOR phar-
macokinetics showing maximum exposure to VOR between 3 and 
6 hours after a 400-mg dose, followed by rapid clearance (4).
We studied resting CD4+ T cells isolated from aviremic 
patients, exposing these cells to 335 nM VOR ex vivo for 6 hours. 
This VOR exposure models the effects achieved after a 400-mg 
oral dose (4). Cells were then washed and placed back into the cul-
ture. To mimic daily, every-other-day, and every-3-day exposure 
to VOR, the cells were then given a second pulse of VOR after an 
18-, 42-, or 66-hour drug-free interval in culture (Figure 2A). As 
expected, we observed a significant increase in cell-associated HIV 
RNA after the initial pulse of VOR (Figure 2B). Consistent with our 
previous in vivo study (8), we observed a consistent dampening of 
the response to VOR when cells received a second VOR exposure 
18 hours after the previous exposure was terminated (Figure 2C). 
Importantly, if the cells were exposed to the second dose of VOR 
after resting for either 42 or 66 hours, we again observed a signifi-
cant increase in cell-associated HIV RNA (Figure 2, D and E), sug-
gesting that more than 18 hours without HDAC inhibitor exposure 
may be necessary to allow the HIV promoter and/or infected cell 
to “reset” and respond to subsequent doses of VOR.
Clinical outcome of single, paired, and multiple doses of VOR. Giv-
en these in vitro pilot data, 16 HIV-infected, aviremic, ART-treat-
ed participants were enrolled in a clinical study with the objective 
of determining the optimal in vivo VOR dosing schedule neces-
sary for effective serial disruption of the CD4+ T cell reservoir. 
VOR dosing of 400 mg was derived from oncology studies, with 
the goal of achieving maximal drug exposure with negligible tox-
icities, as in our original studies (4). An initial leukapheresis eval-
uation was performed to obtain resting CD4+ T cells for quantita-
tion of baseline resting CD4+ T cell infection (RCI) and rca-HIV 
RNA and validation of a measurable response to an ex vivo dose of 
VOR, as previously described (8).
Given the theoretical risks of VOR, the fact that it is unlikely 
that participants would derive clinical benefit from this study, the 
limitations in the number of leukapheresis evaluations that could 
VOR, the pan-HDAC inhibitor panobinostat, or the class I inhib-
itor romidepsin (5–7). In a subsequent study, 5 participants from 
our initial study elected to enter into a multi-dose arm, in which 
VOR was administered daily for 3 days, followed by a 4-day rest 
period, for 6 cycles. Using this regimen, we observed a waning of 
the ability of VOR to consistently and significantly induce RNA 
expression in all patients (8).
To examine this effect, a population pharmacokinetic/phar-
macodynamic model was built from all available daily VOR dosing 
and histone acetylation data for the 5 participants, using nonlin-
ear mixed-effects modeling with NONMEM 7.2 (9). This model 
was used to construct exploratory exposure-effect relationships. 
It showed a clockwise hysteresis loop suggesting that the relation-
ship between VOR concentration and HIV LRA activity is not a 
simple, direct effect. This could result in part from HDAC inhib-
itor effects on host cellular function (10).
Consistent with the potential for complex interactions 
between the cellular effects of HDAC inhibition and the expres-
sion of latent HIV, several studies reported that exposure to HDAC 
inhibitors is associated with a subsequent downregulation of pos-
itive regulators of transcription, such as histone acetyl transferas-
es (HATs) (11, 12). Furthermore, HDAC inhibition can lead to an 
increase in trimethylation of lysine 27 on histone 3 (H3K27me3) 
at transcriptional start sites (12). H3K27me3 is a marker associat-
ed with transcriptional repression. These reports underscore the 
importance of understanding the kinetics of the HIV transcrip-
tional response following serial HDAC inhibitor exposure, to max-
imize HIV LRA activity, and suggest that the effects of such expo-
sure over time may be complex and will require detailed study.
A variety of assays have been used in translational studies to 
assess the reversal of HIV latency in vivo and have most often 
involved PCR-based amplification of cell-associated HIV RNAs 
in a variety of cell populations (13, 14). In order to focus our study 
on the disruption of proviral latency in resting CD4+ T cells in 
the most rigorous way, we elected to assess large numbers of 
Figure 1. Study participant allocation and outcome.
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then later at a 72-hour interval. Six subsequent participants were 
administered paired doses at seventy-two hours. Three partici-
pants with a significant increase in rca-HIV RNA after the sec-
ond dose in the pair (third dose total) then agreed to receive ten 
doses of VOR, given every seventy-two hours. The frequency of 
rca-HIV RNA and RCI frequency was evaluated via leukaphere-
sis after the tenth serial dose of VOR (13th dose total).
The dosing regimen was well tolerated by all patients, with 
some mild, transient gastrointestinal symptoms reported, none 
of which approached grade I, according to the Division of AIDS 
(DAIDS) Toxicity Table for Grading Adverse Events. All 3 par-
ticipants who advanced to the month-long serial dosing phase 
showed a 15%–35% decline in platelet counts that recovered to 
baseline levels when evaluated 4–8 weeks after dosing com-
be performed to precisely measure rca-HIV RNA and resting cell 
infection, and to avoid fruitless VOR exposure for participants in 
whom an endpoint was not quantifiable, continued study evalua-
tion was restricted to those who showed a significant increase in 
rca-HIV RNA after each step of the protocol (Figure 1 and Table 
1). We first confirmed that a significant increase in rca-HIV RNA 
could be measured upon ex vivo exposure.
In those with a measurable ex vivo induction of rca-HIV 
RNA (12 of 16), a single dose of VOR was administered, and rca-
HIV RNA response, safety, and tolerability were ascertained as 
described previously (4). Subsequently, qualified participants 
with a measurable induction of rca-HIV RNA following a single 
dose of VOR (n = 7) received a paired dose of VOR. For 1 par-
ticipant, the doses were administered at a 48-hour interval and 
Figure 2. Ex vivo modeling of serial VOR exposures. (A) Schematic of ex vivo dosing experiment. Resting CD4+ T cells from aviremic participants were 
exposed to media or 335 nM VOR (or PHA as a comparative control) for 6 hours, rca-HIV RNA was measured in an aliquot (B), and the remaining cells were 
washed and placed in culture. Cells then received no VOR or a second 6-hour pulse of VOR at 18 hours, 42 hours, or 66 hours following the first pulse to 
model daily, every-2-day, or every-3-day dosing regimens. rca-HIV RNA was measured in cells that had never been exposed to VOR (circles), were pulsed 
once (squares), or pulsed twice (triangles) at 24 hours (C), 48 hours (D), and 72 hours (E). Each data point represents 1 million resting CD4+ T cells. n = 3 
independent experiments. Data represent the mean ± SD. *P < 0.05,**P < 0.005, and ***P < 0.0001, by Mann-Whitney U test.
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of the 12 participants (Figure 4) and no increase in 4 participants 
(Supplemental Figure 2), although baseline and post-VOR dose 
levels measured in 1 participant (V-12) were very low. In 1 partic-
ipant (V-9), the baseline rca-HIV RNA was unexpectedly higher 
than that measured following dosing (Supplemental Figure 2). 
However, it was retrospectively confirmed that this patient had 
an episode of transient viremia (150 c/ml) immediately prior to 
commencement of the study, potentially confounding the ascer-
tainment of a response to VOR.
pletion. This transient thrombocytopenia never reached the 
threshold to qualify as a grade I adverse event. No other clinical-
ly significant events or drug-related toxicities were observed.
In vivo administration of VOR every 72 hours leads to a sus-
tained increase in rca-HIV RNA. Participants with an increase 
in measurable HIV RNA after ex vivo exposure to VOR were 
administered a single dose of VOR. Among the 16 participants 
enrolled, we were able to measure a significant increase in HIV 
RNA after ex vivo exposure to VOR in the resting CD4+ cells of 
12 (75%) individuals (Figure 3). Among the 
nonresponders, in 1 (V-13), the level of rca-
HIV RNA in the cells before exposure was 
detectable but not quantifiable, and we were 
not able to measure a response to VOR (Sup-
plemental Figure 1; supplemental material 
available online with this article; https://doi.
org/10.1172/JCI92684DS1). In the cells of 1 
participant (V-16) with a high pre-exposure 
rca-HIV RNA level, we detected a marginal 
increase in RNA, even when the cells were 
stimulated with mitogen (Supplemental 
Figure 1). In 2 other participants (V-14 and 
V-15), we detected an increase in HIV RNA 
that did not achieve statistical significance 
(Supplemental Figure 1).
A single in vivo dose of VOR was then 
administered to the 12 individuals men-
tioned above. We observed a measurable 
and significant increase in cell-associated 
RNA in resting CD4+ T cells isolated from 7 
Table 1. Baseline characteristics of the study participants
Participant ID Race Age (yr) CD4 count (cells/μl) Nadir CD4 (cells/μl)A Years of suppression ART regimen Treatment statusB
V-1 White 44 476 232 4.6 EFV, FTC, TDF CHI
V-2 White 61 732 81 6.3 RTV, FTC, TDF, NVP, FPV CHI
V-3 White 57 1,045 338 3.9 ATV, FTC, TDF, RTV CHI
V-4 White 26 474 166 2.0 DRV/r, FTC, TDF CHI
V-5 White 66 610 49 7.5 DRV, ABC, 3TC CHI
V-6 White 49 707 Unavailable 5.2 EFV, FTC, TDF CHI
V-7 White 36 539 313 0.7 RPV, FTC, TDF CHI
V-8 Hispanic 42 850 526 2.0 DRV/r, FTC, TDF CHI
V-9 Black 61 1,302 604 9.2 EFV, FTC, TDF CHI
V-10 White 54 641 157 5.2 RAL, FTC, TDF CHI
V-11 White 49 749 403 6.7 EFV, FTC, TDF AHI
V-12 Black 28 728 840 4.4 ETR, DRV, RTV AHI
V-13 White 57 647 497 5.3 EFV, FTC, TDF AHI
V-14 White 32 766 480 3.0 EFV, FTC, TDF CHI
V-15 Black 26 402 404 0.8 RPV, FTC, TDF CHI
V-16 White 59 789 879 2.8 DRV/r, FTC, TDF CHI
MedianC 49 (26–66) 718 (402–1,302) 403 (49–879) 4.5 (0.7–9.2)
ALowest recorded CD4 cell count in available clinical records. BCHI, treated during chronic HIV infection; AHI, acute HIV infection defined as detectable 
HIV-1 RNA in an antibody-negative or indeterminate sample and initiated ART within 45 days of the estimated date of infection, which was calculated as 
14 days prior to the onset of symptoms consistent with acute retroviral syndrome. CAll participants were men; the median plus the range are shown. EFV, 
efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; RTV, ritonavir; NVP, nevirapine; FPV, fosamprenavir; ATV, atazanavir; DRV/r, darunavir/
ritonavir; ABC, abacavir; 3TC, lamivudine; RAL, raltegravir; ETR, etravirine; RPV, rilpivirine.
Figure 3. A 6-hour exposure to VOR ex vivo increased HIV gag RNA in resting CD4+ T cells isolated 
from aviremic donors. Pools of 24 million resting CD4+ T cells isolated from aviremic donors were 
exposed to 335 nM VOR or mitogen (PHA and 60 U/ml IL-2) for 6 hours, and rca-HIV RNA levels 
were measured. Data represent the mean ± SD. P < 0.05 to P < 0.0001 (Mann-Whitney U test) for all 
comparisons between untreated cells and ex vivo VOR–treated cells.
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Finally, we evaluated the frequency of the replication-compe-
tent latent HIV within the resting CD4+ T cell reservoir by perform-
ing a quantitative viral outgrowth assay (QVOA) at baseline and fol-
lowing paired and multiple VOR doses. Like other studies of latency 
reversal (4–8, 16, 17), we did not observe convincing evidence of a 
significant reduction (>0.3 log10) in the frequency of virus recovered 
in the QVOA (Supplemental Table 1). Not surprisingly, we also did 
not observe any changes in the levels of cell-associated HIV DNA 
following in vivo administration of VOR (data not shown).
Multiple doses of VOR minimally impact immune effector cells 
in vivo. In light of these findings, future studies must seek to 
combine LRAs with modalities to augment the antiviral immune 
response to achieve clearance of persistent HIV infection. 
Therefore, we sought to demonstrate that the administration 
of VOR does not impede the action of effector cell populations 
critical for clearance of antigen-expressing cells. We therefore 
compared the ability of CD8+ T cells isolated from participants 
before, during, and after the receipt of 10 doses of VOR to pro-
liferate following stimulation with HIV peptide pools. As shown 
in Figure 7A, we did not observe a significant change from 
baseline in the ability of CD8+ T cells to proliferate in the pres-
ence of a Flu/EBV peptide pool (FEC), an HIV Gag/Nef pool 
(CTLA), or an HIV non-Gag/Nef peptide pool (CTLB). Further, 
in a viral inhibition assay, the antiviral capacity of CD8+ T cells 
when challenged with autologous targets infected with autolo-
gous reservoir virus (18, 19) tested at effector-to-target (E/T) 
ratios of 1:10 and 1:1 was not significantly altered following 10 
doses of VOR. We observed no reduction in antiviral activity in 
the 3 participants, as analyzed by 1-way ANOVA with post-test 
correction for multiple comparisons (Figure 7B). Finally, during 
the course of the study, we observed a transient but marginal 
decline in absolute lymphocyte counts for some participants 
(Supplemental Table 2) that was resolved within weeks and was 
clinically insignificant.
Discussion
The ability to create a durable window of vulnerability within 
the latent reservoir of HIV infection via the repeated induction 
of viral antigen expression, allowing the clearance of persistent 
infection over a clinically tractable period of time, is paramount 
to developing strategies to eradicate HIV infection. Therefore, 
defining an effective HDAC inhibitor dosing regimen that can 
lead to HIV RNA and subsequent HIV antigen expression is an 
important first step toward this goal. We conducted a stepwise 
pilot study to determine the proper dosing interval for VOR, 
studying 48- and 72-hour intervals.
However, the effort to develop therapies that might clear HIV 
infection is relatively new, and the tools and assays currently at 
hand have limitations. The demonstration of a disruption of HIV 
latency, as measured by increased levels of HIV RNA within rest-
ing CD4+ T cell populations immediately following a single dose 
of VOR (4), was followed by the failure to uniformly observe laten-
cy reversal upon serial dosing of VOR given every 24 hours (8). 
Although the biomarker of the HDAC inhibitor effect, total cellular 
histone acetylation, returns to near-baseline levels within 24 hours 
of a single VOR dose (4), evidence suggests that the cellular effects 
of HDAC inhibitor exposure may be more durable (10, 11, 20–23).
Given the in vitro data suggesting that daily drug exposure 
would blunt the viral response to serial VOR exposure, a conclu-
sion also suggested by the results of our previous clinical trial 
(8), all participants with a significant increase in rca-HIV RNA 
after a single dose of VOR (n = 7) received paired doses at either a 
48-hour or 72-hour interval. Patient V-11 was given a paired dose at 
a 48-hour interval, and as shown in Figure 5A, the increase in HIV 
RNA did not achieve statistical significance. This participant lat-
er received 2 doses of VOR at a 72-hour interval, and we detected 
a significant increase in rca-HIV RNA in resting CD4+ T cells (Fig-
ure 5A). Following this observation, and given anecdotal concerns 
that prolonged alternate-day dosing of VOR might be more diffi-
cult to tolerate, all 6 additional participants received VOR doses 
at the 72-hour interval. We observed a significant increase in rca-
HIV RNA in 5 of these 6 individuals (Figure 5B). Sparse pharmaco-
kinetic sampling of VOR levels near the predicted peak of exposure 
was similar to sampling levels in prior studies (data not shown) (4, 
8). The lack of an increase in rca-HIV RNA in participant V-1 had 
no obvious explanation.
Strategies seeking to eradicate HIV infection are likely to 
require multiple cycles of LRA exposure to induce a sufficient 
display of viral antigen to allow the immune system to identify 
and clear these previously unrecognizable infected cells. To that 
end, 3 of the participants who showed a significant increase in 
rca-HIV RNA after receiving a paired dose of VOR 72 hours apart 
elected to receive 10 consecutive doses of VOR at this interval to 
determine whether HIV RNA expression could be sustained over 
a 1-month period of pulsatile VOR therapy. As shown in Figure 6, 
a significant, sustained increase in HIV RNA was detected in 2 
of the 3 participants. Of note, participant V-5, who did not show 
a continued significant induction of rca-HIV RNA, reported dif-
ficulty with adherence to the 72-hour dosing schedule, deviating 
from the schedule and taking 3 of the 10 doses at shorter inter-
vals. Whether this nonadherence to protocol contributed to the 
lack of a measurable rca-HIV RNA response cannot be deter-
mined. Importantly, as in previous studies,we used a rigorous 
approach to measure rca-RNA, taking steps to minimize RNA 
degradation and ensuring that the increase in rca-HIV RNA mea-
sured after all VOR dosing was not due to baseline RNA variation 
over time (Supplemental Figure 3).
Figure 4. In vivo administration of a single 400-mg dose of VOR led to a 
significant increase in rca-HIV RNA in the resting CD4+ T cells of aviremic 
participants. Data represent the mean ± SD. P < 0.0001 (Mann-Whitney U 
test) for all comparisons between baseline and VOR treatment.
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In studies that have assessed HIV RNA within total popula-
tions of circulating CD4+ T cells, 14 daily doses of VOR (5), pano-
binostat given 3 times per week on alternating weeks (6), and 
once-weekly administration of romidepsin (7) have suggested 
the occurrence of serial latency reversals, although the dose- 
response effects were not consistent in all studies. Episodic vire-
mia has been observed in some studies following HDAC inhibitor 
exposure (7), although it has not been shown that these episodes 
emanate from cells that were formerly latently infected.
Given the strong and uniform evidence in all prior stud-
ies that the initial exposure to the HDAC inhibitor disrupts HIV 
latency, and given the need to ascertain whether latency is serially 
reversed in the most important reservoir of persistent infection — 
resting CD4+ T cells, this study focused on measurements of rca-
HIV RNA following multiple VOR doses.
To accomplish this, we followed a systematic protocol in which 
subsequent dosing was directed by the rca-HIV RNA response of 
each participant in a stepwise fashion. Given the demanding and 
resource-intensive nature of these evaluations, the number of 
participants evaluated is thus far limited, but these initial findings 
provide useful guidance for the design of future studies seeking to 
disrupt latency and clear persistent HIV infection. VOR given in 
this setting was very well tolerated, with only mild and reversible 
declines in platelet counts seen during 1 month of VOR exposure 
and no significant gastrointestinal toxicities.
In 6 of 7 participants who received VOR doses at 72-hour 
intervals, we observed a significant increase in rca-HIV RNA 
levels within circulating resting CD4+ T cells (Figure 5). Three 
of these 7 participants then received serial doses of VOR every 
72 hours for 1 month, and significant increases in rca-HIV RNA 
levels within circulating resting CD4+ T cells (P < 0.01 in three 
and P <0.0001 in three; Figure 5) were still observed following 
the tenth dose of VOR in 2 of the 3 participants. This substan-
tial exposure to VOR was well tolerated, and an assessment of 
Figure 5. Two sequential doses of VOR given every 72 hours, but not 48 hours, resulted in a sustained increase in rca-HIV RNA in participants. (A) 
A 48-hour interval between sequential doses for 1 participant resulted in an increase in rca-HIV RNA levels that only became statistically significant 
when the interval between doses was increased to 72 hours. (B) A significant increase in rca-HIV RNA levels was observed in 5 of 6 additional partici-
pants at the 72-hour interval. Data represent the mean ± SD. **P < 0.01 and ***P < 0.0001, by Mann-Whitney U test. Baseline rca-HIV RNA levels are 
from samples collected at screening, either before the first VOR dose (V-3, V-4, V-5, and V-10), or from a second baseline sample collected prior to the 
paired dosing for participants with more than 1 year of elapsed time from administration of the first dose (V-1, V-2, and V-11).
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immune function following this durable exposure to VOR failed 
to show any sign of reduced proliferation of HIV and non-HIV 
antigens or a reduced antiviral immune response. Nevertheless, 
the reversal of latency over this period did not lead to a deple-
tion of persistent HIV infection in participants who maintained 
their ART. There may be several reasons why we did not observe 
a depletion of the reservoir. First, it is possible that the number 
of doses, even for patients who received 10 doses, was simply 
not enough to result in a measurable depletion of the reservoir. 
Second, the low frequency of latently infected cells in durably 
treated subjects may have caused insufficient chemokine or 
cytokine signaling by cells with reactivated virus, which could 
result in immune-mediated clearance. It is possible that there 
are latently infected cells in immune-privileged sites that, even 
if reactivated by VOR, are poorly accessed by immune cells and 
thus unable to affect virus clearance.
However, as some studies have suggested, depletion of the 
reservoir after latency reversal will most likely require the addi-
tion of an immune intervention to augment HIV-specific immu-
nity. Use of a primary T cell model of HIV latency (24) showed 
that the cytopathic effect induced after latency reversal with 
VOR was insufficient to mediate cell death in the absence of 
global T cell activation. Furthermore, cytotoxic T lymphocytes 
(CTLs) from chronic, ART-treated patients with chronic HIV 
infection inefficiently cleared cells reactivated with VOR, while 
CTLs from elite controllers and CD8+ T cells prestimulated with 
Gag peptides effectively eliminated infected cells, presumably 
because of the high HIV-specific CTL activity of elite control-
lers and ex vivo Gag-stimulated CD8+ T cells. Thus, in many 
patients, the HIV-specific immune response may have waned 
in the absence of recent antigen exposure and/or may be dys-
functional or depleted by HIV disease. Furthermore, Deng et al. 
showed a widespread prevalence of CTL escape mutations in 
viral genomes found in the resting CD4 cell reservoir (25). Nev-
ertheless, there were still some CTLs that recognized virus, and 
their activity could be enhanced by exogenous peptide stimula-
tion. Although some individuals may respond to VOR given at 
shorter intervals, we are currently implementing studies com-
bining immunotherapies with VOR administered at 72-hour 
Figure 6. Multiple (10 doses) of in vivo VOR administered every 72 hours 
resulted in a sustained increase in HIV RNA in 2 of 3 participants. Data 
represent the mean ± SD. ***P < 0.0001, by Mann-Whitney U test.
Figure 7. Repeated exposure to VOR (10 doses) had a limited effect on ex vivo T cell function. (A) Following in vivo exposure to VOR, CD8+ T cell prolifer-
ation in response to Flu peptide (FEC), HIV Gag/Nef peptide (CTLA), and other HIV peptides (CTLB) was evaluated by CFSE staining. Study clinic visits: 4–6 
hours after a single VOR dose (visit 2); 4–6 hours after the second of paired VOR doses (visit 3); 4 hours and 7 months after the last of 10 VOR doses (visits 
4 and 5, respectively). (B) In participants V-3, V-4, and V-5, in vivo exposure to VOR over a 1-month period did not reduce the antiviral capacity of CD8+  
T cells when challenged with autologous targets infected with AR virus in a virus inhibition assay.
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LRA activity that is not measured with our current assays may 
become apparent. Higher doses of VOR, more frequent dosing, 
or VOR administration over a period of more than 4 weeks might 
be considered, but we suspect that such strategies will incur an 
increased frequency of modest clinical toxicities. We view VOR 
as an important tool for research protocols, but improved LRAs 
are clearly needed. Nevertheless, our findings show that VOR 
can provide durable LRA activity, with minimal effects on the 
immune response.
Methods
Clinical protocol. In this phase I–II single-center study, HIV-infected 
participants were recruited if they were receiving stable standard-of-
care ART, with plasma HIV-1 RNA levels consistently below 50 copies/
ml and a CD4 count of more than 300/μl for at least 6 months prior to 
enrollment. Baseline ART was maintained throughout the study. All 
participants were men, 81% of whom were white, 19% black, and 6% 
Hispanic. The median age was 49 [range 26–66] years. At the time of 
study enrollment, all participants were virally suppressed (<50 cop-
ies/ml) for at least 0.7 years (0.7–9.2), with a median CD4 count of 718 
(range, 402–1,302) and a median pre-ART CD4 nadir of 403 (range, 
49–879) at the time of study enrollment (Table 1).
Measurement of cell-associated HIV RNA and DNA. The in vivo 
response to VOR (donated by Merck Research Laboratories) was 
measured as previously described, with minor modifications (4). 
When rca-HIV RNA assays were to be performed, the time of ear-
ly morning VOR dosing was carefully standardized, such that cells 
would be uniformly harvested via apheresis 6 hours later to allow for 
adequate exposure to peak plasma VOR concentrations. Immedi-
ately following leukapheresis, resting CD4+ T cells were isolated as 
reported previously (2) and plated at 1 million cells/well, pelleted, 
snap-frozen, and stored at –80°C. For baseline samples, multiple, 
duplicate cell pellets were frozen and stored, so that at each study 
analysis time point, an untouched but identical baseline sample 
could be processed in parallel and rca-HIV RNA recovered, ampli-
fied, and compared with the rca-HIV RNA recovered from a sample 
of cells exposed to VOR in vivo that had been handled and pro-
cessed simultaneously. Total RNA was isolated from 36 replicates 
of 1 million resting cells using the Magmax 96 Total RNA Isolation 
Kit (Life Technologies, Thermo Fisher Scientific) following the 
manufacturer’s protocol. cDNA was synthesized in duplicate from 
DNase-treated, isolated RNA using the SuperScript III First-Strand 
Synthesis SuperMix Kit (Invitrogen, Thermo Fisher Scientific) 
according to the manufacturer’s protocol. Reverse transcriptase 
was omitted from duplicate wells of each treatment condition, and 
those wells served as controls for DNA contamination. Duplicate 
cDNAs were pooled, and triplicate PCR amplifications were per-
formed using the Bio-Rad CFX96 Real-Time PCR System and pre-
viously published primers and probes (34). A standard curve was 
generated for each PCR reaction as described previously (4). The 
results of the PCR replicates representing each of the original 36 
pools of RNA were averaged, and the SD was determined for each 
condition. The Mann-Whitney U test was used to calculate the sta-
tistical significance of all comparisons.
To measure total cell-associated HIV DNA, 5 million peripher-
al blood mononuclear cells (PBMCs) and 5 million purified resting 
CD4+ T cells from each time point were snap-frozen and stored at 
intervals. Ultimately, studies to address whether LRAs such as 
VOR affect tissue reservoirs and whether cells containing reac-
tivated virus can be cleared from immune-privileged sites will 
have to be included as part of future cure strategies.
We did not observe a statistically significant upregulation 
of rca-HIV RNA ex vivo in 4 of 16 participants, perhaps largely 
because baseline levels of rca-HIV RNA were 10 copies per well 
or fewer in 3 of 4 of these individuals (Supplemental Figure 1). 
In 5 of 12 participants in whom an ex vivo VOR response was 
measured, this response was not seen in vivo. There are numer-
ous possible explanations for this, such as individual differ-
ences in VOR metabolism or distribution or a predominance 
of persistent replication-incompetent proviruses expressing 
measurable HIV RNA levels that mask HIV RNA induced from 
a smaller population of replication-competent proviruses (26–
28). It is also possible that some infected individuals carry a 
predominant population of latent virus that is less responsive to 
VOR, although the only study to address this question thus far 
found that HDAC inhibitors are broadly active across diverse 
viral integrants (29).
Measurements of rca-HIV RNA have limitations, and novel 
assays may improve the study of LRA activity in vivo. Increases 
in resting CD4+ T cell–associated HIV gag p24 antigen and in cir-
culating p24 antigen levels after LRA exposure in vivo have been 
observed using an ultrasensitive assay recently described by 
Howell et al. (30). Further studies will be required to assess the 
ability to measure low levels of protein expression and compare 
rca-HIV RNA measures of latency reversal with antigen-based 
measures of latency reversal.
Although other LRAs are now under study, HDAC inhibitors 
are currently a leading potential therapeutic to attack latent HIV 
infection. It is reasonable to hypothesize that the use of com-
bination therapies to efficiently disrupt latent infection and the 
use of vaccines or immunotherapies to assist in the clearance of 
latent HIV infection will be required to deplete latent, persistent 
HIV infection (31). A recent study combined the administration 
of the HDAC inhibitor romidepsin with an HIV vaccine (32), 
but robust depletion of persistent HIV infection was not noted. 
However, a full understanding of the optimal dosing schedule 
for romidepsin and its interaction with immunotherapies is still 
lacking. As we have previously shown for both CD8 and NK 
cell function in earlier VOR studies (19, 33), in this study, we 
observed no significant effect of VOR on CD8 immune function 
after repeated dosing in vivo.
Careful study of the effects of the kinetics of latency rever-
sal and the interactions of LRAs with the antiviral immune 
response is required to advance toward the ultimate goal of 
developing therapies that can cure HIV infection. Additionally, 
understanding the kinetics of the effects of these compounds 
on host cell function may provide insight into successful clinical 
study design. Here, we have provided guidance to those wishing 
to use VOR as a tool in studies of HIV persistence and suggest 
that the serial administration of 400 mg of the drug every 72 
hours for up to 1 month is likely to be safe and well tolerated. We 
highlight the fact that latency reversal activity is demonstrable 
in the majority of, but not all, participants. However, if effective 
viral clearance strategies can be added in the future, evidence of 
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1% penicillin-streptomycin, and 5 U/ml IL-2. The p24 concentra-
tion in supernatant was assayed by p24 ELISA (ABL Inc.) on day 6.
Statistics. Statistical comparisons between pre- and post-VOR 
exposure groups were analyzed with a Mann-Whitney U test using 
Graph Pad Prism 7.0 software (GraphPad Software). P values of less 
than 0.05 were considered significant. Pools of 36 million resting 
CD4+ T cells from each time point were analyzed for Figures 4–6, 
and as described in the legends for other figures. The mean ± SD is 
reported. For virus inhibition assays, statistical comparisons between 
groups were analyzed by 1-way ANOVA with Dunnett’s post-test cor-
rection for multiple comparisons using GraphPad Prism.
Study approval. This study was reviewed and approved by the 
IRB of the University of North Carolina, the National Institute of 
Allergy and Infectious Diseases (NIAID) Clinical Sciences Review 
Committee, and the FDA. This study is registered at Clinicaltrials.
gov, and clinical trial monitoring was provided by the NIAID. All 
participants provided informed consent prior to their enrollment 
in the study.
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–80°C. DNA was extracted from cells using the DNeasy Blood and 
Tissue Kit (QIAGEN) following the manufacturer’s instructions. 
Amplification of HIV gag DNA was performed in triplicate on a 
Bio-Rad CFX96 Real-Time PCR System using previously published 
primers and probes, and an HIV-1 gag standard was generated as 
previously reported (8, 34, 35).
Quantitative viral outgrowth assay. Lymphocytes were obtained 
by continuous-flow leukapheresis. Isolation of resting CD4+ T cells 
and recovery and quantification of replication-competent virus were 
performed as described previously (36). Briefly, approximately 34 
to 49 million resting CD4+ T cells were plated in replicate-limiting 
dilutions of 2.5 million (12–18 cultures), 0.5 million (6 cultures), and 
0.1 million (6 cultures) cells per well and were activated with phy-
tohemagglutinin (PHA) (Remel Products, Thermo Fisher Scientific), 
a 5-fold excess of allogeneic irradiated PBMCs from a seronegative 
donor, and 60 U/ml IL-2 for 24 hours. Cultures were washed and 
cocultivated with CD8-depleted PBMCs collected from selected 
HIV-seronegative donors screened for adequate CCR5 expression. 
Culture supernatants were harvested on days 15 and 19 and assayed 
for virus production by HIV p24 antigen capture ELISA (ABL Inc.). 
Cultures were scored as positive if p24 was detected on day 15 and 
was increased in concentration on day 19. The number of resting 
CD4+ T cells in infected units per billion (IUPB) was estimated by a 
maximum likelihood method (37, 38).
Peptides. Peptides were synthesized by Sigma-Genosys. HIV-1 
CD8+ T cell optimal epitopes (www.hiv.lanl.gov/content/sequence/
ELF/epitope_analyzer.html) were grouped into pools by protein 
(either Gag/Nef or non-Gag/NEF HIV-1 proteins). In selected donors, 
responses to a pool of influenza, EBV, and CMV CD8+ T cell epitopes 
(39) were also quantified.
T cell proliferation assay. Cryopreserved PBMCs were thawed 
and rested at 37°C overnight in R10, and then pulsed under rotation 
with 5 μM CFSE for 10 minutes. The reaction was quenched with 
ice-cold R10, and excess CFSE was removed by washing twice with 
PBS containing 5% FBS. PBMCs were then incubated with 2 μg/
ml peptide plus 10 units/ml IL-2 at 37°C for 5 days. R10 with 0.5% 
DMSO plus 10 units/ml IL-2 was the negative control, and 3 μg/ml 
PHA plus 10 units/ml IL-2 was the positive control. After 5 days, the 
PBMCs were stained with Zombie NIR Viability Dye, followed by 
CD3–Brilliant Violet 421, CD4–Brilliant Violet 650, CD8–Brilliant 
Violet 510, and CD14/16/19/56-PerCP (dump) (all from BioLeg-
end) and then acquired using a BD LSR II Flow Cytometer. Data 
were analyzed using FlowJo, version 10, and ModFitLT, version 4 
(Verity Software House).
Viral inhibition assay. A unique autologous viral inhibition assay 
was performed as previously described (1, 2). Autologous CD8+ T 
cells were isolated from PBMCs by positive selection (EasySep 
Human CD8+ Selection Kit; STEMCELL Technologies). Autolo-
gous CD8-depleted PBMCs were first activated with 4 μg/ml PHA 
(Remel) and 60 U/ml IL-2 and then infected by spinoculation at 
1,200 g for 90 minutes with either HIV-1 strain JR-CSF or autolo-
gous reservoir (AR) virus at an MOI of 0.01. AR virus was obtained 
from pooled supernatants of replicate wells from outgrowth assays 
of resting CD4+ T cells for each patient. Fifty thousand (5 × 104) 
targets/well were cocultured with CD8+ T cells in triplicate at the 
indicated (Figure 7B) E/T ratio in 0.2 ml conditioned Iscove’s mod-
ified Dulbecco’s medium (cIMDM) supplemented with 10% FBS, 
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